cholesterol metabolism

cholesterol metabolism

the sum of the anabolic and catabolic processes in the synthesis and degradation of cholesterol in the body. Serum cholesterol level is increased when it is ingested and is quickly absorbed. Cholesterol is also synthesized in the liver and can be synthesized by most other body tissues. As more cholesterol is ingested, less is synthesized by the body. Cholesterol is removed from the body by degradation in the liver and excretion in the bile.
References in periodicals archive ?
Brain cholesterol metabolism is unrelated to metabolism in peripheral tissues and the central nervous system (CNS), and plasma cholesterol/lipoprotein compartments are strictly segregated by the blood-brain barrier (BBB).
In this regard, we further studied the effect of cholesterol metabolism.
Likewise sorghum ss-d-glucan extract has also cholesterol-lowering effect and has been shown to regulate hepatic cholesterol metabolism in experimental mice (Kim et al.
2014) confirmed gene expression patterns for the connections between T1AM and the genes that have a crucial role in cholesterol metabolism.
The substantial cost associated with failure of a therapeutic approach in a large outcomes-based clinical trial, as has occurred recently for multiple compounds targeting HDL cholesterol metabolism, has led to intense interest in improved target selection.
Diabetes mellitus may change the brain cholesterol metabolism via insulin level.
Once TMAO makes it to the bloodstream, it is involved in changes in whole-body cholesterol metabolism, platelet function and clot formation, vascular inflammation, and unstable plaque formation in artery walls.
The receptor protein binds certain sugars and surprisingly, it now turns out that the receptor plays an important role in our cholesterol metabolism and potentially related to vascular inflammation, and in whether or not we develop arteriosclerosis in coronary arteries.
Research conducted by the University of Helsinki in Finland has shown that longterm sleep loss can slow down cholesterol metabolism, leading to a heightened risk of cardiovascular disease and illness.
Biotechnology company CTD Holdings (Other OTC:CTDH) said on Monday that it has received responses from the US Food and Drug Administration for its proposed clinical programme for investigating the use of its Trappsol Cyclo drug candidate jn treating Niemann-Pick Type C (NPC), a rare and fatal cholesterol metabolism disease.
These genes are broken up into nine different groups: DNA methylation, mental health, drug metabolism/ chemical detoxification, autism risk, oxalate metabolism, cholesterol metabolism, acetaminophen toxicity, and the transporter genes (see Figure 1, P-41).

Full browser ?